10-Q quarterly report · filed Oct 29, 2026

Fortrea Holdings Inc. (FTRE) Q3 2026 10-Q Quarterly Report

Short answer

Fortrea Holdings Inc. (FTRE) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $692M (down 1.4% year over year) with net income of $600,000.

Q3 2026 key financials · XBRL

Revenue
$692M
−1.4% YoY · +2.0% QoQ
Net income
$600,000
+103.8% YoY · +104.5% QoQ
Operating margin
2.2%
EPS (diluted)
$0.01
+106.3% YoY · +107.1% QoQ

Source: XBRL data from the Fortrea Holdings Inc. (FTRE) Q3 2026 10-Q on SEC EDGAR. USD.

Fortrea Holdings Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $691.5M, down 1.4% YoY from $701.3M, driven by lower clinical development and FSP demand
  • Direct-cost margin 20.2% vs 17.5% YoY, based on direct costs falling to 79.8% of revenue from 82.5%
  • Clinical pharmacology strongest line, revenue increased with higher pass-through costs
  • Cash $220.6M vs $131.3M YoY, operating cash flow $72.7M vs $(15.6)M
  • Backlog $7.3B after $558M scope adjustment, not expected to materially affect near-term revenue expectations

Risk Factors

  • No material changes to risk factors described in the February 26, 2026 Form 10-K
  • Carried-forward business risks remain detailed in Part I, Item 1A of the Annual Report
  • Forward-looking statement risks reiterated in Part I, Item 2 of the Form 10-Q

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Fortrea Holdings Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.